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Background: A clinical trial of mometasone furoate/formoterol fumarate (MF/F)   administered 
via a metered-dose inhaler in subjects with moderate to very severe chronic obstructive 
  pulmonary disease (COPD) investigated the efficacy and safety of a fixed-dose combination 
of MF/F.
Methods: This multicenter, double-blind, placebo-controlled trial had a 26-week treatment 
period and a 26-week safety extension. Subjects (n = 1055; $40 years) were current or 
  ex-smokers randomized to twice-daily treatment with inhaled MF/F 400/10 µg, MF/F 200/10 µg, 
MF 400 µg, F 10 µg, or placebo. The coprimary endpoints of the trial were mean changes from 
baseline in forced expiratory volume in 1 second (FEV1) over 0–12 hours (AUC0–12 FEV1) with 
MF/F versus MF, and in morning predose FEV1 with MF/F versus F. Key secondary endpoints 
were quality of life (Saint George’s Respiratory Questionnaire [SGRQ]), symptom-free nights, 
and partly stable COPD at 26 weeks, as well as time to first COPD exacerbation.
Results: Significant improvements in FEV1 AUC0–12 occurred at endpoint with MF/F 400/10 
and MF/F 200/10 versus MF 400 (P # 0.007). Significant bronchodilation occurred in 5 minutes 
with MF/F, and serial spirometry demonstrated sustained FEV1 improvements with MF/F over 
the treatment period. Significant improvements in morning predose FEV1 occurred with both 
MF/F doses, and these effects were further investigated by excluding results for subjects whose 
morning FEV1 data were collected .2 days after the last dose of study treatment. Improvements 
in SGRQ total scores surpassed the minimum clinically important difference of at least 4 units 
with MF/F 400/10. MF/F 400/10 significantly reduced the time-to-first COPD exacerbation. 
Similar proportions of subjects in all five treatment groups reported treatment-emergent adverse 
events. Rates of pneumonia were low (#1.0%) across treatment groups.
Conclusion: MF/F 400/10 µg twice daily was shown to be an effective therapy for patients 
with moderate to very severe COPD, and both MF/F 400/10 µg twice daily and MF/F 200/10 µg 
twice daily were well tolerated.
Keywords: chronic obstructive pulmonary disease, FEV1, spirometry, exacerbation, inhaled 
corticosteroid, bronchodilator
Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by partially   reversible 
airway obstruction, dyspnea, productive cough, and progressive decline in overall 
health.1,2 Although it may be preventable, COPD is debilitating for many patients 
afflicted with the illness. The classic course of COPD is a gradual downward   spiral 
of lung function and activity level. As COPD worsens, patients are more likely 
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to   experience increasingly reduced functioning, acute 
  exacerbations of COPD,3 comorbid cardiovascular and meta-
bolic disease, and possibly death.1,2,4
Moderate COPD has an estimated worldwide prevalence 
of about 10%, based on data from 9425 patients in 12 cities 
around the world.5 In recent years, COPD has surpassed 
stroke as the third leading cause of death in the US.6,7 
Although COPD is a progressive disease, medications can 
alleviate symptoms, reduce the number and severity of 
exacerbations, and improve overall health status.1,2 In clinical 
practice, bronchodilators relax airway smooth muscle and 
improve lung emptying in patients with COPD.1 Inhaled 
corticosteroids have also been found to provide some clini-
cal improvements in patients with COPD due to their anti-
inflammatory effects.1 Although inhaled corticosteroids do 
not appear to affect the accelerated long-term decline in 
lung function typical of COPD,1 they reduce the number of 
exacerbations and improve health status in patients with more 
advanced disease,1 particularly when used concomitantly 
with an inhaled long-acting beta-agonist (LABA).8 The addi-
tive clinical effects of inhaled corticosteroids when used with 
LABAs8 may be due to synergistic effects via glucocorticoid 
and β2-adrenergic receptor regulation.9,10
The benefits of using concomitant therapy with inhaled 
corticosteroids plus inhaled LABA in the management of 
patients with exacerbations and persistent symptoms (eg, 
dyspnea, night-time awakenings) of COPD are cited by cur-
rent COPD clinical guidelines.1,2,11 The Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) guidelines rec-
ommend addition of an inhaled corticosteroid to long-acting 
bronchodilator therapy for patients with severe COPD (forced 
expiratory volume in 1 second [FEV1] ,50% predicted) and 
repeated exacerbations.2 In 2011 an official statement of 
the American College of Physicians, American College of 
Chest Physicians, American Thoracic Society, and European 
Respiratory Society raised the FEV1 threshold from ,50% 
to ,60% predicted for symptomatic patients with stable 
COPD who may receive combination therapy.12
Currently, three inhaled corticosteroid-LABA com-
binations are available for the treatment of COPD, ie, 
  fluticasone propionate-salmeterol, budesonide-formoterol, 
and   beclomethasone-formoterol. Although investigations 
of several inhaled corticosteroid-LABA combinations in 
the treatment of COPD have been undertaken,13–21 use of 
mometasone furoate with formoterol administered with a 
metered-dose inhaler is a novel combination in this setting. 
Individually, both mometasone furoate and formoterol have 
been shown to be effective in the treatment of COPD,22–24 
and formoterol is approved for use in COPD. A fixed-dose 
combination of MF/F has been shown to be effective for the 
treatment of adolescents and adults with asthma.25–28 The 
combination product of mometasone furoate/formoterol 
fumarate (MF/F) offers both a potent inhaled corticosteroid29 
with relatively low systemic bioavailability30 and a potent, 
selective LABA with fast onset of action.31 These features 
of combined MF/F have the potential to be of benefit to 
patients with COPD. We undertook the present clinical trial, 
a 26-week randomized, placebo-controlled efficacy and safety 
study with a 26-week long-term safety extension, to evaluate 
two therapeutic doses of MF/F in patients with moderate to 
very severe COPD.
Materials and methods
Study design and treatments
This study was a randomized, placebo-controlled, parallel-
group, multicenter, double-blind, double-dummy study 
  (ClinicalTrials.gov identifier: NCT00383435) of MF/F in 
adults with moderate to very severe COPD conducted in 
131 centers located in South America, Asia, Africa, Europe, 
and North America. The sponsor’s statistician produced a 
computer-generated randomization schedule with treatment 
codes in blocks using SAS. Randomization was stratified 
according to the subject’s smoking status at the time of 
randomization. Randomized treatment assignment was 
provided to the investigative site by means of an interactive 
voice response system at the time subjects were randomized. 
To place all prospective participants on the same type of 
treatment and to afford the same opportunity to demonstrate 
improvement in lung function, the study included an open-
label run-in period in which long-acting bronchodilators 
and corticosteroids were discontinued and substituted with 
a short-acting β2-agonist (SABA)-anticholinergic fixed-dose 
combination. Patients were randomly assigned for 26 weeks 
(the treatment period) to one of five double-blind inhaled 
treatments given twice daily, ie, MF/F 400/10 µg, MF/F 
200/10 µg, MF 400 µg, F 10 µg, or placebo (Figure 1). For 
each treatment, patients were instructed to take two inhala-
tions delivered via metered-dose inhaler in order to receive 
the full dose.
After 26 weeks of treatment, all patients randomized to 
placebo were discontinued, while 75% of those receiving 
active treatment were randomly selected to participate in a 
26-week safety extension, continuing on the same treatment. 
We refer to weeks 1 through 52 of this study (the treatment 
period plus the safety extension) as the study period. All 
randomized subjects had study visits at screening, baseline 
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(day 1), and weeks 1, 4, 13, and 26 in the treatment period. 
Subjects in the safety extension had additional visits at weeks 
39 and 52.
Written informed consent was obtained from each patient 
prior to any study-related activity. Prior to study initiation 
at each study site, the clinical study protocol and the written 
informed consent form were reviewed and approved by an 
institutional review board/independent ethics committee.
Patients
We recruited adult males and females who were current or 
former smokers with a smoking history of $10 pack-years. 
Eligible patients were at least 40 years of age and had received 
a diagnosis of moderate to very severe COPD, based on a 
pre-bronchodilator FEV1/forced vital capacity (FVC) ratio 
of #0.70. They must have had symptoms of COPD (chronic 
cough and sputum production not attributable to another 
disease process) for at least 24 months, and a post-broncho-
dilator FEV1 #60% predicted normal and $25% predicted 
normal at screening. Females with childbearing potential 
were required to use a medically acceptable form of birth 
control. We excluded patients who experienced an increase 
in absolute volume of $400 mL at the screening visit or prior 
to the baseline visit within 30 minutes after administration of 
four inhalations of albuterol/salbutamol (total dose of 360 to 
400 µg), or nebulized 2.5 mg albuterol-salbutamol. Patients 
requiring long-term administration of oxygen (.15 hours per 
day) or who experienced an exacerbation of COPD requiring 
medical intervention within four weeks prior to randomiza-
tion, β-blocking agents, or treatment with additional excluded 
medication (other than SABA-short-acting anticholinergic 
to be used as rescue   medication) were not enrolled. Patients 
with a history of   significant medical   illness or a disorder that 
might interfere with the study or that required treatment that 
might interfere with the study were also excluded. Other 
reasons for exclusion included pregnancy or breast-feeding, 
a diagnosis of asthma, lung cancer, or alpha-1-antitrypsin 
deficiency, or a history of lobectomy, pneumonectomy, lung 
volume reduction surgery, cataract extractions in both eyes, 
or other significant ocular problems (glaucoma, trauma, 
opacification).
Outcome measurements and 
assessments
Coprimary endpoints
In order to measure the contribution of each drug treatment 
to the combination, the study used two coprimary efficacy 
endpoints. The first coprimary endpoint was the mean change 
from baseline in FEV1 area under the curve from 0 to 12 hours 
postdose (AUC0–12 h) at the week 13 endpoint (to assess 
the contribution of F 10 to the combination). The second 
coprimary endpoint was the mean change from baseline in 
morning predose FEV1 at the week 13 endpoint (to assess 
the contribution of MF to the combination).
Key secondary endpoints
The study had four key secondary endpoints assessed for 
MF/F 400/10 and MF/F 200/10 at the end of the treatment 
period, ie, change in health status as assessed according to 
total scores on the St George’s Respiratory Questionnaire 
(SGRQ),32 change in symptom-free nights, time-to-first mild, 
moderate, or severe COPD exacerbation, and the proportion 
Screening period
open-label run-in
(SABA/short-acting
anticholinergic FDC)
26-week
double-blind treatment period
26-week double-blind
safety extension
Day-14
Screening
Baseline
(randomization)
Placebo
MF MDI 400 mcg bid
MF/F MDI 400/10 mcg bid
MF/F MDI 200/10 mcg bid
F MDI 10 mcg bid
MF/F MDI 400/10 mcg bida
MF/F MDI 200/10 mcg bida
MF MDI 400 mcg bida
F MDI 10 mcg bida
Figure 1 Study design schematic. 
Note: Total doses were delivered after two inhalations twice daily of the following actuated doses: MF/F 200/5 µg, MF 100/5 µg, MF 200 µg, F 5 µg, or placebo. a75% of each 
group were randomly selected to continue into the safety extension. 
Abbreviations: bid, twice daily; F, formoterol; MDI, metered-dose inhaler; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose combination.
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of patients with partly stable COPD. The SGRQ consists of 
three component scores (symptoms, activity, impact) and a 
total score, each of which ranges from 0 to 100. The better 
SGRQ scores have a lower numeric value. The minimum 
clinically important difference (MCID) for SGRQ scores is 
defined as a 4-point difference from baseline or placebo.33 
A symptom-free night was defined as a combined score of 
0 upon awakening, prior to the use of study drug or rescue 
medication, across three domains, ie, wheezing, cough, and 
difficulty breathing. Partly stable COPD was defined as a 
composite measure of the following outcomes: no use of 
oral steroid rescue medication; no morning or afternoon 
COPD weekly average symptom score .2 during at least 
7 of 8 weeks; no moderate or severe COPD exacerbations; 
no unscheduled visits due to COPD worsening; and no study 
discontinuation due to treatment failure or a treatment-related 
adverse event.
Safety and e-diary assessments
Safety assessments at each study visit included monitor-
ing of treatment-emergent adverse events, vital signs, 
oropharyngeal changes, and forearm bruising. Adverse 
events may have included the onset of new illness and 
the exacerbation of pre-existing conditions (eg, COPD). 
As directed by the study protocol, a medically quali-
fied investigator at each site assessed the relationship of 
adverse events to study treatment, while treatment was 
blinded, as being unlikely, possibly, or probably related 
to treatment. Laboratory assessments, electrocardiogra-
phy, and ophthalmologic examinations were conducted 
at screening and at the final visit. Chylack Incorporated 
(Duxbury, MA) provided guidance for ocular examinations 
and online training to ophthalmologists for Lens Opacities 
Classification System Version III (LOCS III) certification. 
Measurements of bone mineral density and 24-hour plasma 
cortisol were conducted at selected   centers. Dual energy 
x-ray absorptiometry scans of the lumbar spine, left total 
femur, and femoral neck were obtained for a subgroup 
of subjects at selected centers. CCBR-Synarc (Portland, 
OR) provided centralized analysis of the scans, project 
management related to dual energy x-ray absorptiometry, 
and instrument quality control.
Each patient was given an e-diary (CareFusion   Germany, 
234 GmBH Services, Hoechberg, Germany) with a built-in 
spirometer to capture peak expiratory flow and a self-contained 
device to record information about medication use, nocturnal 
awakenings, COPD symptoms, and disease   stability. COPD 
stability was evaluated with a 5-point or 6-point scale (0 = best, 
4–5 = worst) measuring breathlessness, mucus production, 
chest tightness, cough, interference with personal care, and 
interference with outdoor activities.
Statistical analysis
The first coprimary efficacy endpoint (FEV1 AUC0–12) 
compared MF/F 400/10 versus MF 400, MF/F 400/10 
versus placebo, and F 10 versus placebo. All of these com-
parisons had to be statistically significant at this dose level 
of MF/F to assess successfully the contribution of F 10 to 
the   combination. The second coprimary efficacy endpoint 
  (morning predose FEV1) compared MF/F 400/10 versus 
F 10, MF/F 400/10 versus placebo, and MF 400 versus 
placebo. All of these comparisons had to be statistically 
significant at this dose level of MF/F to assess successfully 
the contribution of MF 400 to the combination.
The target sample size was 1000 subjects (200 subjects 
per treatment group). This sample size was considered 
sufficient to detect a difference of 1.2 L × hour between 
MF/F 400/10 and MF 400 in change from baseline FEV1 
AUC0–12 h with 91% power and a two-sided alpha level of 
5% significance, assuming a pooled standard deviation of 
3.6 L × hour. A 1.2 L × hour AUC converts to an average 
difference of 100 mL in FEV1 across 12 hours. A differ-
ence of this magnitude is considered clinically meaning-
ful in subjects with this severity of COPD. For a morning 
predose FEV1 at the week 13 endpoint, the contribution 
of the MF 400 component was expected to be 80 mL for 
a target treatment difference of 160 mL between MF/F 
400/10 and placebo. This treatment difference could be 
detected at 93% power with a two-sided alpha level of 
4.9%, assuming a pooled standard deviation of 230 mL. 
The alpha level was adjusted to allow for a nominal penalty 
of 0.1%. The coprimary comparisons had to be statistically 
significant to proceed with additional efficacy analyses. The 
contribution of MF to the MF/F combination was evaluated 
by analyzing results in subjects whose morning predose 
FEV1 measurements were obtained in the protocol-defined 
time period, using values considered as actual trough FEV1 
values. In a second analysis performed post database lock, 
FEV1 evaluations for each subject performed $2 days 
after the last dose of treatment were excluded, and the 
week 13 morning predose FEV1 endpoint was recalculated 
using the last   remaining evaluation as specified in the 
study protocol.
To assess the coprimary endpoints, an analysis of 
  covariance extracting sources of variation due to treatment, 
  country, smoking status, and baseline as a covariate, was 
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used. Pairwise comparisons were based on least square means 
from the model. An analysis of variance extracting sources 
of variation due to treatment, country, and smoking status, 
was performed also as a confirmatory analysis for these 
treatment comparisons.
Following testing of the coprimary endpoints at a given 
dose level, the key secondary endpoints were analyzed 
sequentially versus placebo. The first two key secondary 
variables (change from baseline in SGRQ total score and 
proportion of COPD symptom-free nights) were assessed 
using the same analysis of covariance as specified for the 
coprimary efficacy variables. The third key secondary vari-
able (proportion of subjects with partly stable COPD) was 
analyzed using the Cochran-Mantel-Haenszel test control-
ling for smoking status. For the fourth key secondary vari-
able (time-to-first mild, moderate, or very severe COPD 
  exacerbation) the log-rank test for equality of survival curves 
was used. Kaplan-Meier curves were used to display these 
treatment responses. In addition, the effect of smoking status 
on the survival curves was examined. Assessments were 
repeated for MF/F 200/10.
Results
Subject disposition and demographics
Of 2313 subjects recruited, 1059 underwent   randomization; 
however, four randomized subjects who had protocol 
  violations were excluded from analyses, leaving 1055 
  randomized patients, two of whom did not receive the study 
drug. A total of 840 patients (80%) completed the treatment 
period, while 215 subjects (20%) discontinued from the 
study early, primarily for reasons unrelated to study treatment 
(Table 1). Treatment groups were well balanced regarding 
baseline demographic characteristics with respect to age, 
race, and sex (Table 2). The treatment groups had similar 
smoking histories.
A total of 529 patients on active treatment continued 
into the safety extension, 472 of whom (89%) completed the 
26-week double-blind extension period. A total of 57 patients 
(11%) did not complete the safety extension. Of these patients, 
17 (3%) discontinued due to adverse events, and 16 (3%) 
discontinued for reasons unrelated to study treatment.
Coprimary efficacy variables
Treatment with MF/F resulted in significant improvements 
in FEV1 which demonstrated the superiority of the combina-
tion versus the individual components. The contribution of 
F 10 to the MF/F 400/10 combination was demonstrated at 
the week 13 endpoint by the statistically significant effect 
of MF/F 400/10 over MF 400 in FEV1 AUC0–12 h (109 mL; 
Table 3). An overall effect size of 163 mL was observed for 
MF/F 400/10 over placebo at this endpoint (P , 0.001). In 
addition, a statistically significant advantage of F 10 mono-
therapy over placebo was demonstrated, with an improvement 
of 74 mL (P = 0.003, Figure 2).
A comparison of MF/F 200/10 with MF 400 mono-
therapy at the week 13 endpoint also demonstrated the 
statistically significant effect of F 10, with an improvement 
of 69 mL (P = 0.007). The significant improvement of FEV1 
AUC0–12 h with MF/F 400/10 versus F 10 (89 mL, P , 0.001) 
confirms the contribution of MF to the combination. The 
improvement of MF/F 200/10 over F 10 was shown to be 
49 mL at this endpoint (P = 0.055). When compared with 
the MF 400 arm, MF/F 400/10 showed a 109 mL improve-
ment at the week 13 endpoint and MF/F 200/10 showed a 
Table 1 Disposition of patients following randomized treatment assignment: number (%) of patients during the treatment period
Subject disposition, n (%) MF/F 200/10 μg 
bid
MF/F 400/10 μg 
bid
MF 400 μg 
bid
F 10 μg 
bid
Placebo Total
Randomized 207 217 210 209 212 1055
Discontinued treatment period 38 (18) 41 (19) 46 (22) 37 (18) 53 (25) 215 (20)
  Adverse event 2 (1) 10 (5) 8 (4) 6 (3) 8 (4) 34 (3)
  Treatment failure 2 (1) 3 (1) 3 (1) 5 (2) 8 (4) 21 (2)
  Lost to follow-up 3 (1) 3 (1) 1 (,1) 2 (1) 2 (1) 11 (1)
    Subject did not wish to continue  
for reasons unrelated to treatment
12 (6) 7 (3) 14 (7) 10 (5) 17 (8) 60 (6)
    Subject did not wish to continue  
for reasons related to treatment
3 (1) 2 (1) 7 (3) 3 (1) 7 (3) 22 (2)
Noncompliance with protocol 5 (2) 1 (,1) 3 (1) 5 (2) 4 (2) 18 (2)
Did not meet protocol eligibility 8 (4) 10 (5) 9 (4) 5 (2) 6 (3) 38 (4)
Administrative 3 (1) 5 (2) 1 (,1) 1 (,1) 1 (,1) 11 (1)
Completed treatment period 169 (82) 176 (81) 164 (78) 172 (82) 159 (75) 840 (80)
Abbreviations: bid, twice daily; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose combination.
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Table 2 Summary of demographic data and baseline characteristics (all randomized subjects)
Characteristics MF/F 200/10 μg bid  
(n = 207)
MF/F 400/10 μg bid  
(n = 217)
MF 400 μg bid  
(n = 210)
F 10 μg bid  
(n = 209)
Placebo 
(n = 212)
Sex, n (%)
  Female 
  Male
46 (22) 
161 (78)
46 (21) 
171 (79)
46 (22) 
164 (78)
57 (27) 
152 (73)
42 (20) 
170 (80)
Age, mean, years (SD) 60.9 (8.1) 59.7 (9.1) 59.8 (8.9) 59.6 (8.5) 58.8 (8.7)
Weight, mean kg (SD) 72.42 (16.46) 72.86 (19.05) 73.46 (18.31) 74.41 (17.37) 73.95 (18.82)
Race, n (%)
  White 
  Black or African American 
  Asian 
  Multiracial
158 (76) 
1 (,1) 
44 (21) 
4 (2)
167 (77) 
0 
44 (20) 
6 (3)
159 (76) 
2 (1) 
42 (20) 
7 (3)
161 (77) 
2 (1) 
40 (19) 
6 (3)
155 (73) 
3 (1) 
46 (22) 
8 (4)
Smoking status, n (%)
  Current smokers 
  Ex-smokers
89 (43) 
118 (57)
99 (46) 
118 (54)
92 (44) 
117 (56)
92 (44) 
117 (56)
97 (46) 
115 (54)
Smoking history, mean pack-years (SD) 41.74 (43.39) 39.73 (28.43) 40.03 (29.28) 40.34 (28.97) 40.29 (37.22)
Abbreviations: bid, twice daily; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose combination; SD, standard deviation.
69 mL improvement. Also at the week 13 endpoint, effect 
sizes of 123 mL for MF/F 200/10 and 163 mL for MF/F 
400/10 over placebo were significant (P , 0.001) and dem-
onstrated the overall benefit of MF/F. The additional benefit 
of 40 mL in the MF/F 400/10 group demonstrated a degree 
of dose-response compared with the MF/F 200/10 group. 
Serial spirometric assessment of FEV1 at the beginning 
(day 1) and end (week 26) of treatment identified the rapid 
onset and sustained duration of bronchodilator effects with 
MF/F (Figure 3).
Substantial evidence indicated the contribution of the 
MF component to the combination, as demonstrated by the 
significant effects on morning predose FEV1 for MF/F 400/10 
and MF/F 200/10 over F 10 alone (111 mL and 58 mL, 
respectively). An overall effect size of 128 mL was observed 
for MF/F 400/10 over placebo (P , 0.001). Although MF/F 
400/10 demonstrated more efficacy than MF/F 200/10 
(P = 0.045), both doses of MF/F demonstrated efficacy 
in this endpoint. Some subjects had FEV1 measurements 
long after they had stopped taking study treatment. In the 
second analysis of morning predose FEV1 which excluded 
subjects in whom FEV1 was measured .2 days after their 
last dose of treatment, a significant difference of 110 mL 
between MF/F 400/10 and F 10 (P , 0.001) confirmed the 
contribution of MF to the combination. Predose FEV1 data, 
collected from the daily diary recorded at the subject’s home 
support the effect observed from spirometry measured at the 
clinic visits.
Key secondary efficacy variables
A 4-point increase over that of placebo (as well as over 
  baseline) is considered the MCID for the SGRQ. MF/F 
400/10 exceeded the MCID of 4 points compared with 
  placebo, with a significant effect size of 4.56 points 
(P = 0.002) for SGRQ total score at the week 26 endpoint. 
In addition, a clinically meaningful difference of 4.12 
points was observed for the MF 400 component, achieving 
significance compared with placebo (P = 0.006), while the 
F 10 component achieved significance with an effect size 
of 3.31 points compared with placebo (P = 0.026). Statis-
tically significant improvements in SGRQ total score for 
MF/F 400/10 over placebo were demonstrated at weeks 4, 
13, and 26 (P # 0.040). MF/F 200/10 did not achieve the 
MCID, with a 2.82-point reduction compared with placebo 
(Figure 4).
The proportion of COPD symptom-free nights was 
improved with MF/F 400/10 (0.15) nights versus placebo 
(0.06) nights, achieving statistical significance (P = 0.001) 
over the 26-week treatment period. However, there was no 
treatment difference between MF/F 400/10 and placebo in 
the proportion of subjects with partly stable COPD at the 
26-week endpoint (last 8 weeks on treatment for each sub-
ject). Percentages ranged from 37.8% to 45.9% across the 
treatment groups.
MF/F 400/10 demonstrated a significant improvement 
over F 10 (P = 0.015) for the time-to-first COPD exacerba-
tion (Figure 5). Subjects treated with MF/F 400/10 had the 
lowest rate of mild, moderate, or severe COPD exacerbations 
across treatments (25.8%), the relative reduction over placebo 
(20.6%) being nominally marginally significant (P = 0.079). 
MF/F 200/10 showed no reduction in mild, moderate, or 
severe exacerbations over placebo, and a 12.1% (P = 0.394) 
relative reduction in moderate or severe exacerbations. 
Since moderate or severe exacerbations are considered more 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
48
Tashkin et alInternational Journal of COPD 2012:7
T
a
b
l
e
 
3
 
C
h
a
n
g
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
i
n
 
s
t
a
n
d
a
r
d
i
z
e
d
 
F
E
V
1
 
A
U
C
0
–
1
2
 
h
 
(
m
L
)
P
 
#
 
0
.
0
0
1
M
F
/
F
 
2
0
0
/
1
0
 
μ
g
 
b
i
d
M
F
/
F
 
4
0
0
/
1
0
 
μ
g
 
b
i
d
M
F
 
4
0
0
 
μ
g
 
b
i
d
F
 
1
0
 
μ
g
 
b
i
d
P
l
a
c
e
b
o
n
 
L
S
 
 
m
e
a
n
 
M
e
a
n
 
 
%
 
c
h
a
n
g
e
a
n
 
L
S
 
 
m
e
a
n
 
M
e
a
n
 
 
%
 
c
h
a
n
g
e
a
n
 
L
S
 
 
m
e
a
n
 
M
e
a
n
 
 
%
 
c
h
a
n
g
e
a
n
 
L
S
 
 
m
e
a
n
 
M
e
a
n
 
 
%
 
c
h
a
n
g
e
a
n
 
L
S
 
 
m
e
a
n
 
M
e
a
n
 
 
%
 
c
h
a
n
g
e
a
B
a
s
e
l
i
n
e
2
0
7
1
2
2
7
2
1
4
1
1
8
6
2
0
7
1
2
5
5
2
0
8
1
2
5
2
2
0
7
1
2
2
7
C
h
a
n
g
e
 
f
r
o
m
 
B
L
 
D
a
y
 
1
2
0
6
1
1
5
*
,
†
1
0
.
8
%
2
1
3
1
3
8
*
,
‡
,
∫
1
2
.
3
%
2
0
5
2
9
4
.
0
%
2
0
7
1
0
0
*
8
.
9
%
2
0
3
1
2
1
.
3
%
 
W
e
e
k
 
1
1
9
0
1
3
7
*
,
†
1
2
.
6
%
1
9
8
1
6
4
*
,
‡
,
∫
1
5
.
2
%
1
8
6
5
6
∫
6
.
1
%
1
9
9
1
0
0
*
9
.
4
%
1
8
3
-
2
0
-
0
.
5
%
 
W
e
e
k
 
1
3
1
8
2
1
3
4
*
,
†
,
∫
1
2
.
2
%
1
8
3
1
7
3
*
,
‡
,
¶
1
5
.
4
%
1
7
5
5
5
6
.
1
%
1
8
3
6
8
∫
6
.
7
%
1
6
7
0
0
%
 
W
e
e
k
 
1
3
 
E
P
b
2
0
7
1
2
6
*
,
†
1
1
.
5
%
2
1
4
1
6
6
*
,
‡
,
¶
1
4
.
8
%
2
0
7
5
7
∫
6
.
6
%
2
0
8
7
7
∫
7
.
4
%
2
0
7
3
0
.
6
%
 
W
e
e
k
 
2
6
1
6
3
1
2
0
*
,
†
9
.
4
%
1
6
7
1
7
0
*
,
‡
,
¶
1
4
.
0
%
1
5
5
5
4
6
.
0
%
1
5
6
6
5
5
.
2
%
1
3
8
1
1
-
0
.
7
%
 
W
e
e
k
 
2
6
 
E
P
b
2
0
7
1
1
0
*
,
†
9
.
3
%
2
1
4
1
5
4
*
,
‡
1
3
.
2
%
2
0
7
5
6
∫
6
.
6
%
2
0
8
7
0
∫
6
.
1
%
2
0
7
0
-
0
.
2
%
N
o
t
e
s
:
 
a
R
a
w
 
m
e
a
n
s
;
 
b
l
a
s
t
 
p
o
s
t
-
b
a
s
e
l
i
n
e
 
n
o
n
-
m
i
s
s
i
n
g
 
r
e
s
u
l
t
 
t
h
r
o
u
g
h
 
t
h
e
 
1
3
-
w
e
e
k
 
o
r
 
2
6
-
w
e
e
k
 
e
v
a
l
u
a
t
i
o
n
 
c
a
r
r
i
e
d
 
f
o
r
w
a
r
d
.
 
T
h
e
 
b
a
s
e
l
i
n
e
 
F
E
V
1
 
w
a
s
 
t
h
e
 
a
v
e
r
a
g
e
 
o
f
 
t
h
e
 
t
w
o
 
p
r
e
d
o
s
e
 
F
E
V
1
 
m
e
a
s
u
r
e
m
e
n
t
s
 
(
3
0
 
m
i
n
u
t
e
s
 
p
r
i
o
r
 
t
o
 
d
o
s
i
n
g
 
a
n
d
 
0
 
h
o
u
r
,
 
i
m
m
e
d
i
a
t
e
l
y
 
p
r
i
o
r
 
t
o
 
d
o
s
i
n
g
)
 
a
t
 
t
h
e
 
b
a
s
e
l
i
n
e
 
v
i
s
i
t
.
 
*
P
 
,
 
0
.
0
0
1
 
v
e
r
s
u
s
 
p
l
a
c
e
b
o
;
 
†
P
 
,
 
0
.
0
5
 
v
e
r
s
u
s
 
M
F
 
4
0
0
;
 
‡
P
 
,
 
0
.
0
0
1
 
v
e
r
s
u
s
 
M
F
 
4
0
0
;
 
¶
P
 
,
 
0
.
0
5
 
v
e
r
s
u
s
 
F
 
1
0
;
 
∫
P
 
#
 
0
.
0
5
 
v
e
r
s
u
s
 
p
l
a
c
e
b
o
.
 
A
b
b
r
e
v
i
a
t
i
o
n
s
:
 
A
U
C
,
 
a
r
e
a
 
u
n
d
e
r
 
c
u
r
v
e
;
 
b
i
d
,
 
t
w
i
c
e
 
d
a
i
l
y
;
 
B
L
,
 
b
a
s
e
l
i
n
e
;
 
E
P
,
 
e
n
d
p
o
i
n
t
;
 
F
,
 
f
o
r
m
o
t
e
r
o
l
;
 
F
E
V
1
,
 
f
o
r
c
e
d
 
e
x
p
i
r
a
t
o
r
y
 
v
o
l
u
m
e
 
i
n
 
1
 
s
e
c
o
n
d
;
 
L
S
,
 
l
e
a
s
t
 
s
q
u
a
r
e
s
;
 
M
F
,
 
m
o
m
e
t
a
s
o
n
e
 
f
u
r
o
a
t
e
;
 
M
F
/
F
,
 
m
o
m
e
t
a
s
o
n
e
 
f
u
r
o
a
t
e
/
f
o
r
m
o
t
e
r
o
l
 
fi
x
e
d
-
d
o
s
e
 
c
o
m
b
i
n
a
t
i
o
n
.
MF/F MDI
200/10
F
E
V
1
 
A
U
C
 
(
m
L
)
MF/F MDI
400/10
MF MDI
400
F MDI 10 Placebo
74 mL
P = 0.003
3
77
57
166
126
200
0
20
40
60
80
100
120
140
160
180
109 mL
P < 0.001
69 mL
P = 0.007
Figure  2 FEV1  AUC0–12  h  week  13  last  observation  carried  forward results  (all 
randomized subjects). 
Abbreviations:  AUC,  area  under  curve;  FEV1,  forced  expiratory  volume  in  1 
second; F, formoterol; MDI, metered-dose inhaler; MF, mometasone furoate; MF/F, 
mometasone furoate/formoterol fixed-dose combination.
clinically important, an additional analysis excluding mild 
exacerbations was performed. This analysis showed that 
subjects on placebo had a higher rate of moderate or severe 
COPD exacerbations (16.5%) than those on MF/F 400/10 
(8.8%; P = 0.009), with a relative reduction for the MF/F 
400/10 combination of 46.7% over placebo.
Safety
Treatment-emergent adverse events
Treatment with MF/F 400/10 and MF/F 200/10 was well 
  tolerated. During the 26-week treatment period, the percent-
age of subjects reporting treatment-emergent adverse events 
was similar between treatment groups, ranging from 26.3% in 
the MF/F 400/10 group to 33.5% in the F 10 group (Table 4). 
The most commonly reported treatment-emergent adverse 
events were headache, upper respiratory tract infection, 
cough, COPD, and hypertension (Table 5). The percentages 
of subjects reporting pneumonia during the 26-week treat-
ment period were low, ranging from 0% to 1.0% across all 
treatment groups.
During the study period (week 1 through week 52), the 
incidence of treatment-emergent adverse events in the active 
treatment groups ranged from 35.9% for MF/F 200/10 to 
42.1% for F 10 (Table 4). The most commonly reported treat-
ment-emergent adverse events among the four active-  treatment 
groups were COPD, headache, nasopharyngitis, upper respira-
tory tract infection, and hypertension (Table 6).
During the treatment period, 68 subjects reported serious 
treatment-emergent adverse events. The most frequently 
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Figure 4 St George’s Respiratory Questionnaire total score change from baseline at week 26 endpoint. 
Note: Treatment with MF/F 400/10 achieved a statistically significant difference from placebo, which satisfied this key secondary endpoint and surpassed the MCID of 4.0. 
Abbreviations: F, formoterol; LS, least squares; MCID, minimum clinically important difference; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-
dose combination; SGRQ, St George’s Respiratory Questionnaire.
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combination.
reported adverse events were oral candidiasis, cough, and 
COPD. There were 16 all-cause mortality events across treat-
ment groups during the 52 weeks of the study. Eleven of the 
deaths occurred during the treatment period (week 1 through 
week 26) and five occurred during the safety extension 
(week 27 through week 52). There were no abnormal, clini-
cally relevant trends in laboratory values, vital signs, bone 
mineral density loss, plasma cortisol levels, ocular changes, 
or new findings of oral candidiasis or forearm bruising. 
Thirteen fractures were reported over the study, comprising 
one in the MF/F 400/10 group (vertebral), three in the MF/F 
200/10 group (two lower limb, one wrist), three in the MF 
400 group (one radius, one facial bone, one rib), five in the 
F 10 group (one each at the radius, ulna, and wrist, and two 
rib), and one in the placebo group (foot).
Rates of pneumonia were low across all treatment groups, 
with no notable differences between the treatment period 
and study period or between the MF-containing and non 
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Figure 5 Time-to-first mild, moderate or severe COPD exacerbation over the 26-week treatment period: Kaplan-Meier survival curves by treatment (all randomized subjects). 
Abbreviations: COPD, chronic obstructive pulmonary disease; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose combination.
MF-containing treatment groups. During the 26-week treat-
ment period, six subjects (0.6%) receiving active treatment 
or placebo reported pneumonia, and over the 52-week study 
period, 11 subjects (1.3%) across the active treatment groups 
reported pneumonia (Table 4). Most cases of pneumonia were 
of moderate severity.
Treatment-related adverse events
During the study, 62 of 843 subjects (7.4%) across the active 
treatment groups reported an adverse event considered by 
the investigator to be treatment-related. The most common 
adverse events considered possibly treatment-related were 
oral candidiasis, cough, and lenticular opacities. Only one case 
of pneumonia (in the placebo group) and one fracture (in the 
F 10 group) were considered possibly treatment-related.
Systemic and ocular effects
No clinically meaningful electrocardiographic changes were 
observed during the study period. Study treatments had mini-
mal effects on the hypothalamic-pituitary-adrenal axis and 
bone mineral density, as measured at selected centers over 
the study period. Baseline 24-hour plasma cortisol levels 
ranged from 190.1 to 220.8 µg/dL ⋅ hour, and small, insignifi-
cant decreases in plasma cortisol were seen across all active 
treatment groups at week 26 and week 52. For bone mineral 
density in the lumbar spine, the region of greatest interest, 
decreases in bone mineral density were ,1% for the MF/F 
200/10 and MF 400 groups. The greatest loss of bone mineral 
density at lumbar spine was -0.6% in the MF 400 group at 
week 26. None of the between-treatment comparisons were 
statistically significant at weeks 26 or 52. Only five subjects 
had a bone mineral density loss at the lumbar spine .6% 
during the study period, comprising two subjects in the MF/F 
200/10 group and three subjects in the MF 400 group.
Ophthalmologic examinations found that between 4.1% 
(MF/F 400/10) and 7.1% (MF 400) of subjects had LOCS 
III increases of $1 unit over the 52-week study period. One 
subject each in the MF/F 200/10 and MF/F 400/10 groups, 
two MF 400 subjects, and one placebo subject reported cata-
racts and were discontinued from the study, as per protocol. 
Additionally, intraocular pressure $22 mmHg was reported 
for four subjects (three on MF/F 400/10 and one on F 10) 
at week 26 and three subjects (one each on MF/F 200/10, 
MF 400, and F 10) at week 52.
Discussion
This clinical study demonstrated efficacy and safety for 
the combination of inhaled MF and F in the treatment of 
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Table 5 Summary of treatment-emergent adverse events $2% incidence (all randomized subjects) during the treatment period
Adverse events, n (%) MF/F 200/10 μg bid  
(n = 207)
MF/F 400/10 μg bid  
(n = 217)
MF 400 μg bid  
(n = 210)
F 10 μg bid  
(n = 209)
Placebo 
(n = 212)
Patients reporting any adverse event 62 (30.0) 57 (26.3) 62 (29.5) 70 (33.5) 67 (31.6)
Chest pain 1 (0.5) 0 1 (0.5) 5 (2.4) 4 (1.9)
Influenza 
Oral candidiasis 
Upper respiratory tract infection
2 (1.0) 
1 (0.5) 
3 (1.4)
1 (0.5) 
3 (1.4) 
6 (2.8)
3 (1.4) 
5 (2.4) 
4 (1.9)
5 (2.4) 
0 
1 (0.5)
2 (0.9) 
2 (0.9) 
5 (2.4)
Headache 8 (3.9) 5 (2.3) 4 (1.9) 8 (3.8) 8 (3.8)
Chronic obstructive pulmonary diseasea 
Cough
3 (1.4) 
3 (1.4)
5 (2.3) 
3 (1.4)
5 (2.4) 
3 (1.4)
6 (2.9) 
6 (2.9)
7 (3.3) 
3 (1.4)
Hypertension 6 (2.9) 2 (0.9) 2 (1.0) 3 (1.4) 5 (2.4)
Note: aIf COPD exacerbation met criteria for a severe AE (eg, was life-threatening, required hospitalization or prolonged hospitalization) it was recorded as an AE. 
Abbreviations: bid, twice daily; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose combination formulation.
Table 4 Summary of treatment-emergent adverse events
Number of subjects (%)
MF/F 200/10 μg bid 
(n = 207)
MF/F 400/10 μg bid 
(n = 217)
MF 400 μg bid 
(n = 210)
F 10 μg bid 
(n = 209)
Placebo bid 
(n = 212)
Treatment period (weeks 1–26)
  Any AE 62 (30.0) 57 (26.3) 62 (29.5) 70 (33.5) 67 (31.6)
  Severe or life-threatening AEs 6 (2.9) 9 (4.1) 15 (7.1) 16 (7.7) 12 (5.7)
  Life-threatening AEs 0 4 (1.8) 4 (1.9) 4 (1.9) 3 (1.4)
  Serious AEs 8 (3.9) 16 (7.4) 15 (7.1) 17 (8.1) 12 (5.7)
  Discontinuations due to AEs 2 (1.0) 10 (4.6) 9 (4.3) 6 (2.9) 8 (3.8)
  Deaths 1 (0.4) 1 (0.4) 3 (1.4) 3 (1.4) 1 (0.4)
  Pneumonia 1 (0.5) 2 (0.9) 0 2 (1.0) 1 (0.5)
  Treatment-related AEs 9 (4.3) 13 (6.0) 12 (5.7) 15 (7.2) 10 (4.7)
Treatment period + safety extension (weeks 1–52)
  Any AE 78 (37.7) 78 (35.9) 86 (41.07) 88 (42.1)
  Severe or life-threatening AEs 7 (3.4) 21 (9.7) 19 (9.0) 24 (11.5)
  Life-threatening AEs 1 (0.5) 6 (2.8) 4 (1.9) 6 (2.9)
  Serious AEs 13 (6.3) 29 (13.4) 22 (10.5) 29 (13.9)
  Discontinuations due to AEs 4 (1.9) 14 (6.5) 13 (6.2) 11 (5.3)
  Deaths 1 (0.4) 3 (1.3) 3 (1.4) 8 (3.8)
  Pneumonia 1 (0.5) 4 (1.8) 2 (1.0) 2 (1.9)
  Treatment-related AEs 12 (5.8) 18 (8.3) 15 (7.1) 17 (8.1)
Abbreviations: AE, adverse event; bid, twice daily; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose combination.
subjects with moderate to very severe COPD and showed 
that each component contributes to the combination. The 
F component demonstrated a significant and clinically 
meaningful contribution to the combination (109 mL) 
based on the comparison of MF/F 400/10 with MF 400 in 
change from baseline in the FEV1 AUC0–12 h at the week 
13 endpoint. The MF component also demonstrated a sig-
nificant contribution to the combination (111 mL) based 
on the comparison of MF/F 400/10 with F 10 in morning 
predose (trough) FEV1 at the week 13 endpoint. The results 
are significant and document a rapid onset of action of 
MF/F within 5 minutes, with significant bronchodilator 
effects that are sustained over the 12-hour dosing interval. 
In addition, the study demonstrates that both the rapidity 
of onset and magnitude of bronchodilation are maintained 
to the end of the 26-week treatment period without any 
evidence of tachyphylaxis. The study had a 12-hour period 
for serial spirometry, which was substantially longer 
than the 1-hour or 2-hour serial spirometry assessments 
in pivotal trials of other inhaled corticosteroids-LABA 
fixed-dose combinations,15,17,18 although a recent trial of 
budesonide-F included serial spirometry data that extended 
for 12 hours.34
A dose-related response for lung function was also 
observed, with MF/F 400/10 showing an additional ben-
efit of 53 mL versus MF/F 200/10, when compared with 
F 10. At the week 13 endpoint, the MF contribution is 
also   demonstrated by the 40 mL change in FEV1 AUC0–12 h 
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between the MF/F 200/10 and MF/F 400/10   combinations, 
since the dose of the F component remains constant and 
only the dose of the MF component is increased. The 
effect seen in both FEV1 AUC0–12 h and morning predose 
FEV1 shows the additive effects of the inhaled corticos-
teroid and LABA components of the combination. At the 
week 13 endpoint, MF 400 showed a 27 mL improvement 
from baseline in morning predose FEV1 and F 10 had no 
improvement at the week 13 endpoint; however, MF/F 
400/10 had a 111 mL improvement at the week 13 endpoint. 
In FEV1 AUC 0–12 h, MF 400 had a 57 mL improvement from 
baseline and F 10 had a 77 mL improvement, whereas 
MF/F 400/10 had a 166 mL improvement. These findings 
are consistent with both preclinical and clinical reports 
of each component enhancing the effect of the other. The 
comparatively greater efficacy of MF/F 400/10 over MF/F 
200/10 on lung function supports a dose-response effect 
of the MF component.
This study demonstrated a clinically relevant improve-
ment in health-related quality of life compared with 
  placebo for both the week 13 and week 26 endpoints, which 
is a clinically significant outcome rarely demonstrated in 
COPD   trials. The MF/F 400/10 arm also demonstrated a 
significant improvement over placebo in the second key 
secondary endpoint of proportion of COPD symptom-free 
nights.
Comparison of the MF/F 400/10 combination with 
placebo showed a nominally significant relative reduction 
of 20.6% in the rate of mild, moderate, or severe exacerba-
tions (P = 0.079). However, the relative reduction of 46.7% 
in moderate to severe exacerbations for the MF/F 400/10 
  combination compared with placebo is significant (P = 0.009) 
and clinically important. Statistically significant reductions 
were also shown for MF/F 400/10 compared with MF and 
F alone, despite a treatment period of only 6 months. His-
torically, it has been difficult to show significant effects 
on exacerbations with pharmacotherapy within this short 
timeframe.
Overall, treatment with MF/F was well tolerated in this 
study. The study demonstrated a low rate of pneumonia in 
all groups, including subjects who received treatments con-
taining an inhaled corticosteroid. In contrast with findings 
of a meta-analysis reporting a dose-related increase in the 
risk of pneumonia with inhaled corticosteroid-containing 
treatments (inhaled corticosteroid monotherapy and inhaled 
corticosteroid-LABA combinations),35 this study did not 
demonstrate any imbalance in the incidence of pneumo-
nia across treatment groups. However, this study was not 
powered to have sufficient numbers or follow-up to detect 
a meaningful difference in pneumonia events, and the low 
event rate prevents any robust conclusions regarding any 
differences between treatment arms for this adverse event. 
In addition, the incidence of oral candidiasis was very low. 
There were no significant demonstrable adverse effects on 
the cardiovascular system, bone mineral density, lenticular 
opacities, or intraocular pressure. Effects on hypothalamic-
pituitary-adrenal axis suppression were quite modest. 
However, longer trials are needed to exclude any long-term 
effects of treatment.
In this study, MF/F was delivered using a metered-dose 
inhaler rather than a dry powder inhaler. This mode of 
administration, in our opinion, offers some advantages. 
Because a metered-dose inhaler requires a lower inspiratory 
flow rate compared with a dry powder inhaler, the amount of 
Table 6 Summary of treatment-emergent adverse events $2% incidence (all randomized subjects) during the study period
Adverse events, n (%) MF/F 200/10 μg bid  
(n = 207)
MF/F 400/10 μg bid  
(n = 217)
MF 400 μg bid  
(n = 210)
F 10 μg bid 
(n = 209)
Subjects reporting any adverse event 78 (37.7) 78 (35.9) 86 (41.0) 88 (42.1)
Chest pain 1 (0.5) 0 1 (0.5) 5 (2.4)
Influenza 
Nasopharyngitis 
Oral candidiasis 
Respiratory tract infection 
Upper respiratory tract infection
2 (1.0) 
4 (1.9) 
1 (0.5) 
3 (1.4) 
3 (1.4)
2 (0.9) 
7 (3.2) 
4 (1.8) 
2 (0.9) 
8 (3.7)
5 (2.4) 
7 (3.3) 
5 (2.4) 
5 (2.4) 
5 (2.4)
6 (2.9) 
3 (1.4) 
0 
3 (1.4) 
4 (1.9)
Back pain 
Headache
3 (1.4) 
8 (3.9)
1 (0.5) 
8 (3.7)
2 (1.0) 
6 (2.9)
5 (2.4) 
8 (3.8)
Chronic obstructive pulmonary disease* 
Cough
4 (1.9) 
4 (1.9)
13 (6.0) 
4 (1.8)
6 (2.9) 
4 (1.9)
10 (4.8) 
6 (2.9)
Hypertension 9 (4.3) 4 (1.8) 3 (1.4) 3 (1.4)
Note: *If COPD exacerbation met criteria for a severe adverse event (eg, was life-threatening, required hospitalization or prolonged hospitalization) it was recorded as an 
adverse event. 
Abbreviations: bid, twice daily; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose combination.
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medication deposited in the oral cavity and the glottic area 
is reduced, which potentially accounts for the low incidence 
of oral candidiasis and dysphonia demonstrated during 
the study period. The generally finer particle sizes gener-
ated by metered-dose inhalers allow for greater lung and 
  peripheral lung deposition. Additionally, patients with 
severe lung impairment may have difficulty generating 
adequate inspiratory force to allow for effective use of 
some dry powder   inhalers. However, it is important for 
patients to be adequately instructed on appropriate use 
of both dry powder inhalers and metered-dose inhaler 
devices. Both devices have been associated with a similar 
percentage of errors.36
In conclusion, the results of this study show MF/F 
400/10 µg twice daily to be an effective therapy for patients 
with moderate to very severe COPD, based on improvements 
in lung function and quality of life as well as reduction in 
COPD exacerbations. Both MF/F 400/10 µg twice daily and 
MF/F 200/10 µg twice daily were well tolerated.
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